Yup - agree with that - and with friend @footnort above.
I think the desired sequence would be:
- Fast-track designation
- Accelerated approval : ie conditional approval for clinical commercial use, with requirement for a follow up Ph 3 to confirm the clinical/survival benefit
- If they get that, then BP will be begging for a partnership or licensing deal, which would include their backing for the Ph 3
Things could move quite rapidly - for Azer-cel and Vaxinia.
With further good clinical benefit outcomes, IMU would get a deal, or deals, bringing cash flow and a partner to fund confirmatory Ph 3 trials.
Cheers
Dave
Media Thread, page-10770
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
0.001(2.22%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| 4.5¢ | 4.7¢ | 4.5¢ | $906.2K | 19.67M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 9543864 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.6¢ | 1266571 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |